These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 16213667)

  • 1. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
    Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
    Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
    Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation.
    Buyyounouski MK; Hanlon AL; Horwitz EM; Uzzo RG; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1291-8. PubMed ID: 15817330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis.
    Satoh T; Ishiyama H; Matsumoto K; Tsumura H; Kitano M; Hayakawa K; Ebara S; Nasu Y; Kumon H; Kanazawa S; Miki K; Egawa S; Aoki M; Toya K; Yorozu A; Nagata H; Saito S; Baba S
    BJU Int; 2009 Apr; 103(8):1064-8. PubMed ID: 19040526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSA bounce after prostate brachytherapy with or without neoadjuvant androgen deprivation.
    McGrath SD; Antonucci JV; Fitch DL; Ghilezan M; Gustafson GS; Vicini FA; Martinez AA; Kestin LL
    Brachytherapy; 2010; 9(2):137-44. PubMed ID: 19850537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.
    Buyyounouski MK; Hanlon AL; Eisenberg DF; Horwitz EM; Feigenberg SJ; Uzzo RG; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1455-62. PubMed ID: 16169682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: a study of 295 patients with a minimum 3-year followup.
    Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM
    Brachytherapy; 2006; 5(2):122-6. PubMed ID: 16644467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
    Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
    Am J Clin Oncol; 2006 Oct; 29(5):458-62. PubMed ID: 17023779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
    Akyol F; Ozyigit G; Selek U; Karabulut E
    Eur Urol; 2005 Jul; 48(1):40-5. PubMed ID: 15967250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis.
    Horwitz EM; Levy LB; Thames HD; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
    Cancer; 2006 Oct; 107(7):1496-502. PubMed ID: 16944536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy.
    Pickles T;
    Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1355-9. PubMed ID: 16406391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Lief JH; Hinerman-Mulroy A; Galbreath RW
    Brachytherapy; 2003; 2(3):181-8. PubMed ID: 15062141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis.
    Horwitz EM; Thames HD; Kuban DA; Levy LB; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Hanks GE; Zietman AL
    J Urol; 2005 Mar; 173(3):797-802. PubMed ID: 15711272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome.
    Bachand F; Martin AG; Beaulieu L; Harel F; Vigneault E
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):679-84. PubMed ID: 18963537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy.
    Crook J; Gillan C; Yeung I; Austen L; McLean M; Lockwood G
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):426-33. PubMed ID: 17869662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment predictors of posttreatment PSA doubling times for patients undergoing three-dimensional conformal radiotherapy for clinically localized prostate cancer.
    Beard C; Chen MH; Cote K; Loffredo M; Renshaw A; Hurwitz M; D'Amico AV
    Urology; 2005 Nov; 66(5):1020-3. PubMed ID: 16286116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces?
    Thompson A; Keyes M; Pickles T; Palma D; Moravan V; Spadinger I; Lapointe V; Morris WJ
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):415-21. PubMed ID: 20133083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.